Cells 1: 569-579) using chicken erythrocytes, and the chorioallantoic fluid containing the virus was stored as the recombinant Sendai virus vector-containing composition of this invention at -80°C.

REMARKS

Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date 8-12-02

By _____

Shanks & Herbert
1033 N. Fairfax Street
Alexandria, VA 22314
Telephone: 703-683-3600
Facsimile: 703-683-9785

Shelly Guest Cermak
Attorney for Applicant
Registration No. 39,571

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 50-0622 for any such fees; and applicant(s) hereby petition for any needed extension of time.

MARKED UP VERSION ATTACHED TO AMENDMENT IN

SERIAL NO. 09/843,922

Marked up version of the paragraph starting at page 11, lines 2-8 is below:

Figure 1 schematically shows a method for constructing the replication competent seV comprising a foreign gene, such as for GFP or β-glucuronidase. Using primer 1 **(SEQ ID NO: 1)**, which has a *Not*I site, and primer 2 **(SEQ ID NO: 2)**, which comprises, a transcription termination signal (R2), an intervening sequence (IG), a transcription initiation sequence (R1) and a *Not*I site, the ORF of a foreign gene is amplified by PCR and inserted into the *Not*I site **(SEQ ID NO: 3)** of pUC18/T7HVJRz.DNA (+18).

Marked up version of the paragraph on page 31, lines 1-36 is below:

The recombinant Sendai virus vector was constructed similarly as in Example 1 according to the method described in literatures (Kato, A. et al., EMBO J. 16: 578-598, 1997; Hasan, M. K. et al., J. Gen. Virol. 78: 2813-2820, 1997). First, an 18 bp spacer sequence having the *Not*I restriction site [5'-(G)-CGGCCGCAGATCTTCACG-3'] (~~SEQ ID NO: 1~~)**(SEQ ID NO: 4)** was inserted into the contiguous loci between the leader sequence and 5'-terminus of the nucleotide sequence encoding the N protein of the cloned Sendai virus genomic cDNA [pSev(+)] to obtain the plasmid pSeV18+b(+) containing the self-cleaving ribozyme site derived from the antigenomic strand of hepatitis delta virus. To insert the hGDNF gene (containing the stop codon; 636 bp) into the *Not*I site of the plasmid pSeV18+b(+), primers containing the *Not*I site and an additional set of Sendai virus E and S signal sequence tags 5'-ACTTGCGGCCGCCAAAGTTCATCTAT GAAGTTATGGGATGTCGTGGC-3' (~~SEQ ID NO: 2~~) **(SEQ ID NO: 5)** and 5'- ACTTGCGGCCGCGATGAACTTTCACCCTAAGTTTTTCTTACTACGGTCAGATACATCC ACACCTTTTAGCGG-3'(~~SEQ ID NO: 3~~) **(SEQ ID NO: 6)** were prepared (*Not*I site underlined). Human GDNF gene fragments were amplified by the polymerase chain reaction using these primers and human GDNF gene as

the template, and inserted into the *NotI* site of the plasmid containing SeV genomic cDNA. Plasmid containing the template Sendai virus genome containing the GDNF gene and the plasmids (pGEM-N), pGEM-P, and pGEM-L) encoding N-protein, P-protein and L-protein, respectively, were complexed with the commercially available active type dendrimer molecule (SuperFect Transfection Reagent; Qiagen). LLCMK2 cells were transformed together with the above-prepared complexes and the vaccinia virus vT7-3 (Fuerst, T. R. et al., Proc. Natl. Acad. Sci. USA 83: 8122-8126, 1986; Kato, A. et al., Genes Cells 1: 569-579, 1996). After 40 h, cells were disrupted by repeating freezing and thawing three times, and injected into the chorioallantoic membrane of a chicken egg containing a 10-day-old embryo. Then, the virus was recovered, and the vaccinia virus was eliminated by passage in eggs. The virus titer was determined by the hemagglutination activity (HA) (Kato, A. et al., 1996, Genes Cells 1: 569-579) using chicken erythrocytes, and the chorioallantoic fluid containing the virus was stored as the recombinant Sendai virus vector-containing composition of this invention at -80°C.